Revolutionizing early autism detection with science-based, non-invasive testing powered by microbial metabolites
With our breakthrough MDM™ urine panel, children as young as 2 years old can be reliably tested for metabolic and microbial markers associated with autism.
This early, non-invasive testing empowers families and clinicians to take action before critical years of brain development are lost.
Early intervention starts with early detection
Many children with autism go undiagnosed for years. Our goal is to change that—by delivering sensitive, specific, and accessible diagnostic tools
Our patented Microbial-Derived Metabolite (MDM™) system uses a simple urine sample to deliver unmatched diagnostic clarity
This non-invasive approach makes testing more accessible—especially for children with sensory sensitivities or behavioral challenges
Unlike competing tests, our solution offers:
Our MDM test has achieved unmatched specificity, meaning zero false positives—a critical standard for meaningful diagnosis.
Our precision (>90%) metabolomics approach detects unique microbial and metabolic markers commonly elevated in children with autism, outperforming current commercial alternatives.
Our report includes actionable suggestions that support targeted interventions, enabling clinicians and families to make personalized treatment decisions.
We go beyond detecting risk of autism: our test provides insights into underlying biological imbalances—including gut microbial disruptions—that may contribute to ASD symptoms.
Most available tests lack accuracy, provide no insight into root causes, and offer no direction for next steps—leaving families with more questions than answers.
Easy-to-use, non-invasive urine sample collection kit
Advanced metabolomic profiling using our proprietary MDM system
Actionable insights delivered to caregivers and clinicians

seeking clarity and answers for
their children

looking for specialized
lab support

integrating biomedical
testing into care

in the autism and
microbiome space